Question 1

Does Envestnet Asset Management own CYTK stock?

Accepted Answer

Yes. As of its Q2 2026 13F, Envestnet Asset Management holds 88,521 shares of CYTK (Cytokinetics), worth $7.5M.

Question 2

How many shares of CYTK does Envestnet Asset Management own?

Accepted Answer

As of its Q2 2026 13F, Envestnet Asset Management holds 88,521 shares of CYTK (Cytokinetics).

Question 3

What is Envestnet Asset Management's CYTK position worth?

Accepted Answer

As of its Q2 2026 13F, Envestnet Asset Management's CYTK position is worth $7.5M.

Question 4

Is Envestnet Asset Management buying or selling CYTK?

Accepted Answer

In Q2 2026, Envestnet Asset Management increased its CYTK position by 53,984 shares (+156.3%).

Question 5

When did Envestnet Asset Management first buy CYTK?

Accepted Answer

Envestnet Asset Management first reported CYTK in its Q1 2020 13F and has listed it in 26 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Increased	88,521	+156.3%	$7.5M	0.0%	$85.19	44
2026-Q1	Decreased	34,537	-45.0%	$2.3M	0.0%	$65.91	0
2025-Q4	Increased	62,733	+6.2%	$4M	0.0%	$63.54	28
2025-Q3	Increased	59,068	+100.5%	$3.2M	0.0%	$54.96	43
2025-Q2	Increased	29,467	+21.2%	$973,590	0.0%	$33.04	30
2025-Q1	Decreased	24,321	-8.1%	$977,461	0.0%	$40.19	0
2024-Q4	Decreased	26,455	-20.0%	$1.2M	0.0%	$47.04	0
2024-Q3	Increased	33,067	+8.0%	$1.7M	0.0%	$52.80	28